Metagenomi Therapeutics Cash on Hand 2022-2025 | MGX
Metagenomi Therapeutics cash on hand from 2022 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
|
Metagenomi Therapeutics Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2024 | $248 |
| 2023 | $271 |
| 2022 | $362 |
| 2021 | $108 |
|
Metagenomi Therapeutics Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2025-09-30 | $184 |
| 2025-06-30 | $205 |
| 2025-03-31 | $226 |
| 2024-12-31 | $248 |
| 2024-09-30 | $275 |
| 2024-06-30 | $300 |
| 2024-03-31 | $327 |
| 2023-12-31 | $271 |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | $362 |
| 2021-12-31 | $108 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.057B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.352B | 12.21 |
| BridgeBio Pharma (BBIO) | United States | $14.131B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.864B | 18.45 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.944B | 24.10 |
| Bausch Health Cos (BHC) | Canada | $2.255B | 1.60 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.314B | 9.47 |
| Taysha Gene Therapies (TSHA) | United States | $1.276B | 0.00 |
| Personalis (PSNL) | United States | $0.790B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.433B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.184B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |